VAERS Explorer
Back to explore

Report #2880641

Received Jan 5, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
IA
Recovered
Not recovered
Vaccinated
Dec 9, 2025
Onset
Dec 1, 2025
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALSUNK5N79ZIM

Symptoms (2)

Injection site pruritusInjection site scab

Symptom narrative

Itchy spot at injection site; And a scab keeps appearing; This non-serious case was reported by a other health professional and described the occurrence of injection site itching in a 70-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 5N79Z) for prophylaxis. On 09-DEC-2025, the patient received Arexvy (intramuscular) .5 ml. In DEC-2025, less than 3 weeks after receiving Arexvy, the patient experienced injection site itching (Verbatim: Itchy spot at injection site) and injection site scab (Verbatim: And a scab keeps appearing). The outcome of the injection site itching and injection site scab were not resolved. It was unknown if the reporter considered the injection site itching and injection site scab to be related to Arexvy. It was unknown if the company considered the injection site itching and injection site scab to be related to Arexvy. Additional Information: GSK Receipt Date: 26-DEC-2025 The patient had an itchy spot at the injection site and a scab kept appearing.